



Supporting Information

for

One-pot synthesis of 2-arylated and 2-alkylated benzoxazoles and benzimidazoles based on triphenylbismuth dichloride-promoted desulfurization of thioamides

Arisu Koyanagi, Yuki Murata, Shiori Hayakawa, Mio Matsumura and Shuji Yasuike

Beilstein J. Org. Chem. **2022**, *18*, 1479–1487. doi:10.3762/bjoc.18.155

Experimental procedures, characterization data and copies of spectra

Table of contents

1. General information	S1
2. Synthesis of triphenylbismuth dichloride (Ph_3BiCl_2)	S1
3. Synthesis of 2-substituted benzoxazoles	S2
4. Synthesis of 2-substituted benzimidazoles	S9
5. References	S12
6. Copies of ^1H , ^{13}C , and ^{19}F NMR spectra	S13
7. NMR Experiments	S50

1. General information

Unless otherwise stated, all reagents and solvents were purchased from commercial suppliers and were used without further purification. ^1H NMR (TMS: δ 0.00 ppm, CHCl_3 : δ 7.26 ppm or DMSO: δ 2.50 ppm as an internal standard), ^{13}C NMR (CDCl_3 : δ 77.0 ppm or DMSO- d_6 : δ 39.5 ppm as an internal standard) and ^{19}F NMR (trifluoromethylbenzene: δ -64.0 ppm as an internal standard) spectra were recorded on a JEOL ECZ-400S (400 MHz, 100 MHz and 376 MHz) spectrometer in CDCl_3 and DMSO- d_6 . Melting points were measured on a Yanagimoto micro melting point hot stage apparatus and are uncorrected. GC-MS (EI) spectra were recorded on an Agilent 5977E Diff-SST MSD-230V spectrometer. HRMS (ESI) were measured on an Agilent 6230 TOF mass spectrometer. IR spectra were recorded on an FTIR-8400S system from Shimadzu spectrometer and are reported in frequency of absorption (cm^{-1}). Only selected IR absorbencies are reported. All chromatographic separations were accomplished with Silica Gel 60N (Kanto Chemical Co., Inc.). Thin-layer chromatography (TLC) was performed with Macherey-Nagel Sil G25 UV254 pre-coated TLC plates. Aminophenols **1a–k**, *N*-phenylthiobenzamide (**2a**) and BiCl_3 were purchased from TCI Fine Chemicals, Japan. Thiobenzamides **2b–m**^[1] and *N*-tosyl-*o*-phenylenediamine (**15**)^[2] were prepared according to the reported procedures.

2. Synthesis of triphenylbismuth dichloride (Ph_3BiCl_2).

To a solution of prepared triphenylbismuth^[3] (10.0 g, 22.7 mmol) in dry CH_2Cl_2 (60 mL) was added SO_2Cl_2 (2.02 mL, 3.37 g, 25.0 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 h until complete consumption of the starting material, as monitored by TLC. The resulting mixture was evaporated under reduced pressure and remaining whitish solids were purified by recrystallization from CH_2Cl_2 /hexane (9.98 g, 86%, m.p. 151-153 °C). The product was confirmed by comparison of the melting point (lit. m.p. 149-150 °C) and NMR data with that in the literature^[4].

3. Synthesis of 2-substituted benzoxazoles.

A mixture of aminophenol **1** (0.5 mmol), *N*-phenylthiobenzamide **2** (1.0 mmol), and Ph₃BiCl₂ (**6a**: 1.0 mmol) were well stirred at 60 °C in 1,2-DCE (3.0 mL) for 18 h. After completion of the reaction, the reaction mixture was diluted with H₂O (20 mL) and CH₂Cl₂ (20 mL), and the aqueous phase was extracted with CH₂Cl₂ (3 × 30 mL). The combined organic phase was washed with brine (20 mL) and dried over MgSO₄. Evaporation of the solvent furnished the crude product. The crude product was then purified by column chromatography on silica gel.

2-Phenylbenzoxazole (8a)^[5]

91.7 mg (94%). Colorless needles. m.p. 102-103 °C (from Hexane); *R*_f = 0.5 (Hexane/EtOAc 9:1). ¹H NMR (400 MHz, CDCl₃): δ = 8.28-8.24 (m, 2H; Ar-H), 7.79-7.75 (m, 1H; Ar-H), 7.59-7.56 (m, 1H; Ar-H), 7.53-7.48 (m, 3H; Ar-H), 7.37-7.33 (m, 2H; Ar-H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 163.2 (C), 150.9 (C), 142.2 (C), 131.7 (CH), 129.0 (CH), 127.7 (CH), 127.3 (C), 125.2 (CH), 124.7 (CH), 120.1 (CH), 110.7 (CH) ppm. MS (EI): *m/z* (%): 195 (100, M⁺), 167 (17), 63 (14); HRMS: *m/z* [M⁺] calcd for C₁₃H₉NO: 195.0684. Found: 195.0681.

2-(4-Methoxyphenyl)benzoxazole (8b)^[5]

107 mg (95%). Colorless prisms. m.p. 95-97 °C (from Hexane), *R*_f = 0.3 (Hexane/EtOAc 9 : 1); ¹H NMR (400 MHz, CDCl₃): δ = 8.19 (dt, *J* = 8.8, 2.8 Hz, 2H; Ar-H), 7.75-7.73 (m, 1H; Ar-H), 7.57-7.54 (m, 1H; Ar-H), 7.35-7.30 (m, 2H, Ar-H), 7.02 (dt, *J* = 9.2, 2.8 Hz, 2H; Ar-H), 3.89 (s, 3H; OMe) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 163.3 (C), 162.5 (C), 150.7 (C) 142.2 (C), 129.6 (CH), 124.8 (CH), 124.6 (CH), 119.7 (CH), 114.5 (CH), 110.5 (CH), 55.6 (CH₃) ppm. MS (EI): *m/z* (%): 225 (100, M⁺), 210 (31), 182 (37), 127 (6); HRMS: *m/z* [M⁺] calcd for C₁₄H₁₁NO₂: 225.0790. Found: 225.0786.

2-(*p*-Tolyl)benzoxazole (8c)^[6]

101 mg (97%). Colorless prisms. m.p. 111-112 °C (from Hexane), *R*_f = 0.4 (Hexane/EtOAc 9 : 1); ¹H NMR (400 MHz, CDCl₃): δ = 8.14 (d, *J* = 8.4 Hz, 2H; Ar-H), 7.78-7.74 (m, 1H; Ar-H), 7.59-7.55 (m, 1H; Ar-H), 7.36-7.25 (m, 4H; Ar-H), 2.44 (s, 3H; Me) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 163.4 (C), 150.8 (C), 142.3 (C), 142.2 (C), 129.8 (CH), 127.7 (CH), 125.0 (CH), 124.6 (CH), 124.5 (C), 120.0 (CH), 110.6 (CH), 21.8 (CH₃) ppm. MS (EI): *m/z* (%): 209 (100, M⁺), 180 (8), 91 (4). HRMS: *m/z* [M⁺] calcd for C₁₄H₁₁NO: 209.0841. Found: 209.0838.

2-(4-Chlorophenyl)benzoxazole (8d)^[5]

113 mg (99%). Pale yellow prisms. m.p. 143-145 °C (from Hexane), R_f = 0.3 (Hexane/EtOAc 9:1); ^1H NMR (400 MHz, CDCl₃): δ = 8.19 (dt, J = 8.8, 2.8 Hz, 2H; Ar-H), 7.78-7.74 (m, 1H; Ar-H), 7.60-7.56 (m, 1H; Ar-H), 7.50 (dt, J = 8.8, 2.4 Hz, 2H; Ar-H), 7.36 (dt, J = 9.2, 4.4 Hz, 2H; Ar-H) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 162.2 (C), 150.8 (C), 142.0 (C), 137.9 (C), 129.4 (CH), 129.0 (CH), 125.7 (C), 125.5 (CH), 124.9 (CH), 120.2 (CH), 110.8 (CH) ppm. MS (EI): m/z (%): 229 (100, M⁺), 201 (11), 166 (4). HRMS: m/z [M⁺] calcd for C₁₃H₈CINO: 229.0294. Found: 229.0297.

2-(4-Bromophenyl)benzoxazole (8e)^[5]

126 mg (92%). Yellow needles. m.p. 158-161 °C (from Hexane), R_f = 0.5 (Hexane/EtOAc 9:1); ^1H NMR (400 MHz, CDCl₃): δ = 8.11 (dt, J = 8.8, 1.6 Hz, 2H; Ar-H), 7.78-7.74 (m, 1H; Ar-H), 7.65 (dt, J = 8.4, 2.0 Hz, 2H; Ar-H), 7.59-7.55 (m, 1H; Ar-H), 7.38-7.33 (m, 2H; Ar-H) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 162.3 (C), 150.9 (C), 142.1 (C), 132.4 (CH), 129.1 (CH), 126.4 (C), 126.2(C), 125.5 (CH), 124.9 (CH), 120.2 (CH), 110.8 (CH) ppm. MS (EI): m/z (%): 273 (100, M⁺), 245 (9), 194 (12), 166 (9). HRMS: m/z [M⁺] calcd for C₁₃H₈BrNO: 272.9789. Found: 272.9785.

2-[4-(Trifluoromethyl)phenyl]benzoxazole (8f)^[6]

104 mg (79%). Colorless needles. m.p. 135-138 °C (from Hexane), R_f = 0.4 (Hexane/EtOAc 9:1). ^1H NMR (400 MHz, CDCl₃): δ = 8.38 (d, J = 7.6 Hz, 2H; Ar-H), 7.82-7.78 (m, 3H; Ar-H), 7.64-7.61 (m, 1H; Ar-H), 7.42-7.36 (m, 2H; Ar-H) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 161.6 (C), 151.0 (C), 142.0 (C), 133.1 (q, $^2J_{\text{C},\text{F}}$ = 32.6 Hz, C), 130.6 (C), 128.0 (CH), 126.0 (q, $^3J_{\text{C},\text{F}}$ = 3.8 Hz, CH), 125.2 (CH), 125.1 (CH), 123.8 (q, $^1J_{\text{C},\text{F}}$ = 271 Hz, C), 120.5 (CH), 110.9 (CH) ppm; ^{19}F NMR (376 MHz, CDCl₃): δ = -62.9 (s) ppm. MS (EI): m/z (%): 263 (100, M⁺), 235 (13), 63 (19). HRMS: m/z [M⁺] calcd for C₁₄H₈F₃NO: 263.0558. Found: 263.0557.

2-(4-Nitrophenyl)benzoxazole (8g)^[7]

124 mg (99%). Orange prisms. m.p. 255-258 °C (from CH₂Cl₂-EtOH), R_f = 0.8 (Hexane/EtOAc 9:1); ^1H NMR (400 MHz, CDCl₃): δ = 8.43 (dt, J = 9.2, 2.0 Hz, 2H; Ar-H), 8.38 (dt, J = 9.2, 2.0 Hz, 2H; Ar-H), 7.84-7.82 (m, 1H; Ar-H), 7.65-7.62 (m, 1H; Ar-H), 7.46-7.39 (m, 2H; Ar-H) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 160.8 (C), 151.1 (C), 149.5 (C), 142.0 (C), 132.9 (C), 128.5 (CH), 126.5 (C), 125.4 (C), 124.4 (CH), 120.8 (CH), 111.1 (CH) ppm. IR (KBr): ν = 3093, 2360, 1521, 1450, 1348, 1338, 1057, 854 cm⁻¹. MS (EI): m/z (%): 240 (100, M⁺), 210 (45), 194 (27), 116 (8). HRMS: m/z [M⁺] calcd for C₁₃H₈N₂O₃: 240.0535. Found: 240.0539.

2-(o-Tolyl)benzoxazole (8h)^[5]

93.1 mg (89%). Colorless needles. m.p. : 65-67 °C (from Hexane), R_f = 0.5 (Hexane/EtOAc 9:1); ^1H (400 MHz, CDCl₃): δ = 8.18-8.16 (m, 1H; Ar-H), 7.81-7.79 (m, 1H; Ar-H), 7.60-7.58 (m, 1H; Ar-H), 7.43-7.40 (m, 1H; Ar-H), 7.38-7.32 (m, 4H; Ar-H), 2.81 (s, 3H; Me); ^{13}C NMR (100 MHz, CDCl₃): δ = 163.5 (C), 150.4 (C), 142.2 (C), 139.0 (C), 131.9 (CH), 131.0 (CH), 130.1 (CH), 126.4 (C), 126.2 (CH), 125.1 (CH), 124.5 (CH), 120.3 (CH), 110.6 (CH), 22.4 (CH₃) ppm. MS (EI): m/z (%): 209 (100, M⁺), 180 (40), 152 (8), 116 (5). HRMS: m/z [M⁺] calcd for C₁₄H₁₁NO: 209.0841. Found: 209.0837.

2-Mesitylbenzoxazole (8i)^[8]

92.5 mg (78%). Pale yellow oil. R_f = 0.5 (Hexane/EtOAc 9:1); ^1H NMR (400 MHz, CDCl₃): δ = 7.84-7.80 (m, 1H; Ar-H), 7.60-7.56 (m, 1H; Ar-H), 7.40-7.56 (m, 2H; Ar-H), 6.97 (s, 2H; Ar-H), 2.35 (s, 3H; Me), 2.29 (s, 6H; Me) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 163.4 (C), 150.7 (C), 141.7 (C), 140.4 (C), 138.6 (C), 128.8 (CH), 125.1 (C), 125.0 (CH), 124.3 (CH), 120.3 (CH), 110.7 (CH), 21.5 (CH₃), 20.5 (CH₃) ppm. MS (EI): m/z (%): 237 (100, M⁺), 222 (22), 208 (21), 194 (7). HRMS: m/z [M⁺] calcd for C₁₆H₁₅NO: 237.1154. Found: 237.1156.

2-(Naphthalen-1-yl)benzoxazole (8j)^[9]

111 mg (91%). Yellow plates. m.p. 104-107 °C (from Hexane), R_f = 0.6 (Hexane/EtOAc 9:1); ^1H NMR (400 MHz, CDCl₃): δ = 9.46 (d, J = 8.8 Hz, 1H; Ar-H), 8.43 (dd, J = 6.0, 1.0 Hz, 1H; Ar-H), 8.03 (d, J = 8.0 Hz, 1H; Ar-H), 7.94 (d, J = 8.0 Hz, 1H; Ar-H), 7.90-7.88 (m, 1H; Ar-H), 7.71 (ddd, J = 8.4, 6.8, 1.6 Hz, 1H; Ar-H), 7.67-7.59 (m, 3H; Ar-H), 7.42-7.39 (m, 2H; Ar-H) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 162.9 (C), 150.3 (C), 142.4 (C), 134.1 (C), 132.5 (CH), 130.8 (C), 129.5 (CH), 128.8 (CH), 128.1 (CH), 126.6 (CH), 126.4 (CH), 125.4 (CH), 125.1 (CH), 124.6 (CH), 123.7 (C), 120.4 (CH), 110.7 (CH) ppm. MS (EI): m/z (%): 245 (100, M⁺), 216 (9), 153 (8). HRMS: m/z [M⁺] calcd for C₁₇H₁₁NO: 245.0841. Found: 245.0839.

2-(Thiophen-2-yl)benzoxazole (8k)^[5]

96.7 mg (96%). Pale yellow prisms. m.p. 99-102 °C (from Hexane), R_f = 0.5 (Hexane/EtOAc 9:1); ^1H NMR (400 MHz, CDCl₃): δ = 7.91 (dd, J = 3.6, 0.8 Hz, 1H; Ar-H), 7.75-7.71 (m, 1H; Ar-H), 7.56-7.53 (m, 2H; Ar-H), 7.36-7.31 (m, 2H; Ar-H), 7.18 (dd, J = 3.6, 0.8 Hz, 1H; Ar-H) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 159.2 (C), 150.5 (C), 142.1 (C), 130.4 (CH), 130.1 (CH), 129.7 (C), 128.4 (CH), 125.2 (CH), 124.9 (CH), 119.9 (CH), 110.6 (CH) ppm. MS (EI): m/z (%): 201 (100, M⁺), 173 (9), 92 (3). HRMS: m/z [M⁺] calcd for C₁₁H₇NOS: 201.0248. Found: 201.0244.

2-Cyclohexylbenzoxazole (8l)^[10]

97.7 mg (97%). Yellow oil. R_f = 0.5 (Hexane/EtOAc 9:1); ^1H NMR (400 MHz, CDCl_3): δ = 7.68-7.66 (m, 1H; Ar-H), 7.47-7.45 (m, 1H; Ar-H), 7.30-7.26 (m, 2H; Ar-H), 2.98-2.92 (m, 1H; Cy), 2.18-2.14 (m, 2H; Cy), 1.89-1.83 (m, 2H; Cy), 1.75-1.64 (m, 3H; Cy), 1.47-1.25 (m, 3H; Cy) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ = 170.6 (C), 150.6 (C), 141.1 (C), 124.5 (CH), 124.2 (CH), 119.7 (CH), 110.4 (CH), 38.0 (CH), 30.6 (CH_2), 25.9 (CH_2), 25.8 (CH_2) ppm. MS (EI): m/z (%): 201 (12, M^+), 172 (18), 146(100), 120 (6). HRMS: m/z [M $^+$] calcd for $\text{C}_{13}\text{H}_{15}\text{NO}$: 201.1154. Found: 201.1151.

2-Methylbenzoxazole (8m)^[11]

53.3 mg (80%). Colorless oil, R_f = 0.5 (Hexane/EtOAc 9:1). ^1H NMR (400 MHz, CDCl_3): δ = 7.66-7.62 (m, 1H; Ar-H), 7.47-7.43 (m, 1H; Ar-H), 7.28-7.25 (m, 2H; Ar-H), 2.63 (s, 3H; Me) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ = 163.9 (C), 151.1 (C), 141.6 (C), 124.6 (CH), 124.2 (CH), 119.5 (CH), 110.3 (CH), 14.7 (CH_3) ppm. MS (EI): m/z (%): 133 (100, M^+), 104 (20), 63 (21). HRMS: m/z [M $^+$] calcd for $\text{C}_8\text{H}_7\text{NO}$: 133.0528. Found: 133.0530.

5-Methoxy-2-phenylbenzoxazole (8n)^[5]

113 mg (99%). Colorless needles. m.p. 65-68 °C (from Hexane), R_f = 0.4 (Hexane/EtOAc 9:1); ^1H NMR (400 MHz, CDCl_3): δ = 8.24-8.21 (m, 2H; Ar-H), 7.52-7.44 (m, 3H; Ar-H), 7.45 (d, J = 8.7 Hz, 1H; Ar-H), 7.28-7.25 (m, 1H; Ar-H), 6.94 (dd, J = 9.1, 2.7 Hz, 1H; Ar-H), 3.87 (s, 3H; Me) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ = 163.9 (C), 157.5 (C), 145.5 (C), 142.9 (C), 131.6 (CH), 129.1 (CH), 127.6 (CH), 127.3 (C), 113.9 (CH), 110.9 (CH), 102.9 (CH), 56.1 (CH_3) ppm. MS (EI): m/z (%): 225 (100, M^+), 210 (71), 107 (22). HRMS: m/z [M $^+$] calcd for $\text{C}_{14}\text{H}_{11}\text{NO}_2$: 225.0790. Found: 225.0788.

5-Methyl-2-phenylbenzoxazole (8o)^[6]

87.5 mg (84%). Colorless plates. m.p. 96-98 °C (from Hexane), R_f = 0.4 (Hexane/EtOAc 9:1); ^1H NMR (400 MHz, CDCl_3): δ = 8.25-8.23 (m, 2H; Ar-H), 7.53-7.50 (m, 3H; Ar-H), 7.49-7.44 (m, 1H; Ar-H), 7.45 (d, J = 8.7 Hz; 1H, Ar-H), 7.16 (dd, J = 8.2, 0.9 Hz, 1H; Ar-H), 2.48 (s, 3H; Me) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ = 163.2 (C), 149.0 (C), 142.2 (C), 134.6 (C), 131.6 (CH), 129.0 (CH), 127.7 (CH), 127.3 (C), 126.4 (CH), 120.0 (CH), 110.1 (CH), 21.7 (CH_3) ppm. MS (EI): m/z (%): 209 (100, M^+), 180 (9), 105 (5). HRMS: m/z [M $^+$] calcd for $\text{C}_{14}\text{H}_{11}\text{NO}$: 209.0841. Found: 209.0845.

5-Bromo-2-phenylbenzoxazole (8p)^[6]

129 mg (94%). Red prisms. m.p. 106-108 °C (from Hexane), R_f = 0.4 (Hexane/EtOAc 9:1); ^1H NMR (400 MHz, CDCl₃): δ = 8.25-8.23 (m, 2H; Ar-H), 7.90 (s, 1H; Ar-H), 7.58-7.50 (m, 3H; Ar-H), 7.46 (s, 2H; Ar-H) ppm. ^{13}C NMR (100 MHz, CDCl₃): δ = 164.3 (C), 149.9 (C), 143.8 (C), 132.1 (CH), 129.1 (CH), 128.2 (CH), 127.9 (CH), 126.7 (C), 123.1 (CH), 117.5 (C), 112.0 (CH) ppm. MS (EI): *m/z* (%): 273 (100, M⁺), 245 (11), 143 (6). HRMS: *m/z* [M⁺] calcd for C₁₃H₈BrNO: 272.9789. Found: 272.9792.

2-Phenyl-5-(trifluoromethyl)benzoxazole (8q)^[6]

130 mg (99%). Colorless plates. m.p. 75-77 °C (from Hexane), R_f = 0.5 (Hexane/EtOAc 9:1); ^1H NMR (400 MHz, CDCl₃): δ = 8.26 (dd, *J* = 9.6, 1.8 Hz, 2H; Ar-H), 8.04 (s, 1H; Ar-H), 7.68 (d, *J* = 8.2 Hz, 1H; Ar-H), 7.61 (dd, *J* = 6.4, 1.6 Hz, 1H; Ar-H), 7.58-7.52 (m, 3H; Ar-H) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 164.9 (C), 152.6 (C), 142.3 (C), 132.3 (CH), 129.2 (CH), 128.0 (CH), 127.4 (q, $^1J_{\text{C},\text{F}}$ = 271 Hz, C), 126.6 (C), 124.3 (q, $^2J_{\text{C},\text{F}}$ = 36.4 Hz; C), 122.4 (q, $^3J_{\text{C},\text{F}}$ = 2.9 Hz; CH), 117.8 (q, $^3J_{\text{C},\text{F}}$ = 3.8 Hz; CH), 111.2 (CH) ppm; ^{19}F NMR (376 MHz, CDCl₃): δ = -61.0 (s) ppm. MS (EI): *m/z* (%): 263 (100, M⁺), 235 (16), 132 (7). HRMS: *m/z* [M⁺] calcd for C₁₄H₈F₃NO: 263.0558. Found: 263.0555.

5-Nitro-2-phenylbenzoxazole (8r)^[12]

132 mg (99%). Colorless needles. m.p. 167-169 °C (from Hexane), R_f = 0.4 (Hexane/EtOAc 8:2). ^1H NMR (400 MHz, CDCl₃): δ = 8.64 (d, *J* = 2.3 Hz, 1H; Ar-H), 8.32 (dd, *J* = 8.7, 2.3 Hz, 1H; Ar-H), 8.27-8.25 (m, 2H; Ar-H), 7.68 (d, *J* = 9.2 Hz, 1H; Ar-H), 7.63-7.53 (m, 3H; Ar-H) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 166.1 (C), 154.4 (C), 145.5 (C), 142.7 (C), 132.8 (CH), 129.3 (CH), 128.2 (CH), 126.1 (C), 121.3 (CH), 116.4 (CH), 110.9 (CH) ppm. IR (KBr): ν = 3099, 2341, 1616, 1527, 1448, 1350, 1338, 1265, 1238, 1066, 1022, 819 cm⁻¹. MS (EI): *m/z* (%): 240 (100, M⁺), 210 (19), 194 (38), 91 (34). HRMS: *m/z* [M⁺] calcd for C₁₃H₈N₂O₃: 240.0535. Found: 240.0539.

4-Methyl-2-phenylbenzoxazole (8s)^[5]

99.3 mg (95%). Reddish needles. m.p. 83-85 °C (from Hexane), R_f = 0.4 (Hexane/EtOAc 9:1). ^1H NMR (400 MHz, CDCl₃): δ = 8.28-8.25 (m, 2H; Ar-H), 7.53-7.50 (m, 3H; Ar-H), 7.40 (d, *J* = 8.2 Hz, 1H; Ar-H), 7.23 (t, *J* = 8.0 Hz, 1H; Ar-H), 7.14 (dt, *J* = 7.3, 0.9 Hz, 1H; Ar-H), 2.68 (s, 3H; Me) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 162.4 (C), 150.6 (C), 141.5 (C), 131.4 (CH), 130.7 (CH), 129.0 (CH), 127.7 (CH), 127.5 (C), 125.2 (CH), 124.9 (CH), 108.0 (CH), 16.8 (CH₃) ppm. MS (EI): *m/z* (%): 209 (100, M⁺), 180 (18), 105 (11), 78 (31). HRMS: *m/z* [M⁺] calcd for C₁₄H₁₁NO: 209.0841. Found: 209.0842.

6-Methyl-2-phenylbenzoxazole (8t)^[5]

98.1 mg (94%). Colorless plates. m.p. 83-84 °C (from Hexane), R_f = 0.4 (Hexane/EtOAc 9:1). ^1H NMR (400 MHz, CDCl₃): δ = 8.25-8.20 (m, 2H; Ar-H), 7.63 (d, J = 8.2 Hz, 1H; Ar-H), 7.53-7.45 (m, 3H; Ar-H), 7.38 (s, 1H; Ar-H), 7.16 (dd, J = 7.8, 0.9 Hz, 1H; Ar-H), 2.50 (s, 3H; Me) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 162.7 (C), 151.1 (C), 140.0 (C), 135.7 (C), 131.5 (CH), 129.0 (CH), 127.6 (CH), 127.4 (C), 126.0 (CH), 119.4 (CH), 110.9 (CH), 22.0 (CH₃) ppm. MS (EI): m/z (%): 209 (100, M⁺), 180 (15), 105 (12), 78 (32). HRMS: m/z [M⁺] calcd for C₁₄H₁₁NO: 209.0841. Found: 209.0837.

7-Methyl-2-phenyl-benzoxazole (8u)^[13]

57.8 mg (55%). Brown oil. R_f = 0.4 (Hexane/EtOAc 9:1). ^1H NMR (400 MHz, CDCl₃): δ = 8.29-8.24 (m, 2H; Ar-H), 7.59 (d, J = 7.8 Hz, 1H; Ar-H), 7.54-7.51 (m, 3H; Ar-H), 7.24 (t, J = 7.3 Hz, 1H; Ar-H), 7.14 (d, J = 7.8 Hz, 1H; Ar-H), 2.60 (s, 3H; CH₃) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 162.8 (C), 150.1 (C), 141.8 (C), 131.5 (CH), 129.0 (CH), 127.7 (CH), 127.5 (C), 126.2 (CH), 124.6 (CH), 121.3 (C), 117.4 (CH), 15.4 (CH₃) ppm. MS (EI): m/z (%): 209 (100, M⁺), 106 (27), 78 (27). HRMS: m/z [M⁺] calcd for C₁₃H₈CINO: 209.0841. Found: 209.0840.

2-Phenylnaphtho[2,3-d]oxazole (8v)^[5]

103 mg (84%). Pale yellow needles. m.p. 202-204 °C (from Hexane), R_f = 0.3 (Hexane/EtOAc 9:1). ^1H NMR (400 MHz, CDCl₃): δ = 8.35-8.33 (m, 2H; Ar-H), 8.20 (s, 1H; Ar-H), 8.02-7.95 (m, 3H; Ar-H), 7.61-7.53 (m, 3H; Ar-H), 7.52-7.47 (m, 2H; Ar-H) ppm. ^{13}C NMR (100 MHz, CDCl₃): δ = 165.1 (C), 149.8 (C), 142.0 (C), 132.3 (CH), 131.9 (C), 131.7 (C), 129.1 (CH), 128.7 (CH), 128.3 (CH), 128.0 (CH), 127.0 (C), 125.6 (CH), 124.9 (CH), 117.4 (CH), 106.5 (CH) ppm. MS (EI): m/z (%): 245 (100, M⁺), 217 (13), 140 (9), 114 (30). HRMS: m/z [M⁺] calcd for C₁₇H₁₁NO: 245.0841. Found: 245.0845.

2-Phenylanthra[2,3-d]oxazole (8w)

71.0 mg (48%). Yellow needles. mp : 254-257 °C (from Toluene), R_f = 0.5 (Hexane/EtOAc 8:2). ^1H NMR (400 MHz, CDCl₃): δ = 8.62 (s, 1H; Ar-H), 8.55 (s, 1H; Ar-H), 8.38-8.35 (m, 3H; Ar-H), 8.08 (s, 1H; Ar-H), 8.02-8.00 (m, 2H; Ar-H), 7.62-7.55 (m, 3H; Ar-H), 7.48-7.42 (m, 2H; Ar-H) ppm; ^{13}C NMR (100 MHz, CDCl₃): δ = 165.8 (C), 149.9 (C), 132.5 (CH), 131.5 (C), 130.9 (C), 130.38 (C), 130.36 (C), 129.1×2 (CH, C), 128.5 (CH), 128.1 (CH), 127.8 (CH), 127.0 (CH), 126.9 (C), 126.1 (CH), 125.5 (CH), 125.2 (CH), 117.0 (CH), 105.4 (CH) ppm. IR (KBr): ν = 3047, 2359, 1616, 1546, 1485, 1448, 1261, 1188, 1047, 1020, 895 cm⁻¹. MS (EI): m/z (%): 295 (100, M⁺), 190 (9), 163 (34). HRMS: m/z [M⁺] calcd for C₂₁H₁₃NO: 295.0997. Found: 295.0995.

2-Phenylbenzthiazole (9)^[12]

98.3 mg (93%). Pale yellow needles. m.p. 122-125 °C, (from Hexane), R_f = 0.6 (Hexane/EtOAc 8:2); ^1H NMR (400 MHz, CDCl_3): δ = 8.10-8.07 (m, 3H; Ar-H), 7.90 (d, J = 7.2 Hz, 1H; Ar-H), 7.51-7.47 (m, 4H; Ar-H), 7.38 (t, J = 8.4 Hz, 1H; Ar-H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ = 168.2 (C), 154.3 (C), 135.2 (C), 133.7 (C), 131.1 (CH), 129.2 (CH), 127.7 (CH), 126.5 (CH), 125.3 (CH), 123.4 (CH), 121.8 (CH) ppm. MS (EI): m/z (%): 211 (100, M^+), 184 (4), 108 (20). HRMS: m/z [M $^+$] calcd for $\text{C}_{13}\text{H}_9\text{NS}$: 211.0456. Found: 211.0460.

Methyl 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylate (12)^[14]

A mixture of methyl 4-amino-3-hydroxybenzoate (**10**: 0.5 mmol), *N*-phenylthiobenzamide derivative (**11**: 1.0 mmol), and Ph_3BiCl_2 (**6a**: 1.0 mmol) were well stirred at 60 °C in 1,2-DCE (3.0 mL) for 18 hr. After completion of the reaction, the reaction mixture was diluted with H_2O (20 mL) and CH_2Cl_2 (20 mL), and aqueous phase was extracted with CH_2Cl_2 (3 × 30 mL). The combined organic phase was washed with brine (20 mL) and dried over MgSO_4 . Evaporation of the solvent furnished the crude product. The crude product was then purified by silica gel column chromatography to give desired product (**12**).

148 mg (91%). Colorless prisms. m.p. 165-168 °C (from CH_2Cl_2 -Hexane), R_f = 0.40 (Hexane/EtOAc 8:2); ^1H NMR (400 MHz, CDCl_3): δ = 8.28 (d, J = 0.8 Hz, 1H; Ar-H), 8.16 (d, J = 1.6 Hz, 2H; Ar-H), 8.12 (dd, J = 8.0, 1.2 Hz, 1H; Ar-H), 7.80 (d, J = 8.0 Hz, 1H; Ar-H), 7.55 (t, J = 1.6 Hz, 1H; Ar-H), 3.97 (s, 3H; OMe) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ = 166.5 (C), 163.0 (C), 150.6 (C), 145.6 (C), 136.1 (CH), 132.0 (CH), 129.5 (C), 128.1 (C), 126.9 (CH), 126.3 (CH), 120.2 (CH), 112.6 (CH), 52.7 (CH_3) ppm. IR (KBr): ν = 3078, 2360, 1730, 1546, 1435, 1413, 1286, 1267, 1242, 1230, 987, 860 cm^{-1} . MS (EI): m/z (%): 321 (57, M^+), 290 (100), 234 (30), 145 (18). HRMS: m/z [M $^+$] calcd for $\text{C}_{15}\text{H}_9\text{Cl}_2\text{NO}_3$: 320.9959. Found: 320.9991.

Tafamidis (13)^[12]

Benzoxazole derivatives (**12**: 0.5 mmol) was dissolved in a mixture of THF (3.0 mL), MeOH (1.0 mL), and H_2O (1.0 mL) and treated with anhydrous LiOH (2.0 mmol) at room temperature for 12 h. The reaction mixture was acidified to pH 4.0 with 1N HCl aq. and extracted with EtOAc. The combined organic layer was dried over MgSO_4 , filtered and concentrated to give the product **13**.

140 mg (92%). Colorless prisms. m.p. 260 °C (decomp. from THF- H_2O), R_f = 0.2 (EtOAc). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 13.2 (brs, 1H; OH), 8.25 (d, J = 1.2 Hz, 1H; Ar-H), 8.12 (d, J = 2.4 Hz, 2H; Ar-H), 8.00 (dd, J = 7.6, 1.2 Hz, 1H; Ar-H), 7.94-7.90 (m, 1H; Ar-H), 7.89 (d, J = 8.8 Hz, 1H; Ar-H) ppm; ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ = 167.2 (C), 162.6 (C), 150.6 (C),

145.3 (C), 135.8 (C), 132.3 (CH), 129.8 (C), 129.3 (C), 127.1 (CH), 126.5 (CH), 120.6 (CH), 112.8 (CH) ppm. IR (KBr): ν = 2924, 2360, 1697, 1546, 1437, 1419, 1307, 1296, 1273, 862, 773 cm⁻¹. HRMS: *m/z* [M-H]⁻ calcd for C₁₄H₆Cl₂NO₃: 305.9730. Found: 305.9734.

4. Synthesis of 2-substituted benzimidazoles.

A mixture of *N*-tosyl-*o*-phenylenediamine (**15**: 0.5 mmol), *N*-phenylthiobenzamide (**2**: 1.0 mmol), and Ph₃BiCl₂ (**6a**: 1.0 mmol) were well stirred at 60 °C in 1,2-DCE (3.0 mL) for 18 h. After completion of the reaction, the reaction mixture was diluted with H₂O (20 mL) and CH₂Cl₂ (20 mL), and aqueous phase was extracted with CH₂Cl₂ (3 × 30 mL). The combined organic phase was washed with brine (20 mL) and dried over MgSO₄. Evaporation of the solvent furnished the crude product. The crude product was then purified by column chromatography on silica gel.

2-(4-Methoxyphenyl)-1-tosyl-1*H*-benzimidazole (**16b**)^[15]

143 mg (76%). Colorless plates. m.p. 119-122 °C (from CH₂Cl₂-Hexane), *R_f* = 0.4 (Hexane/EtOAc 7:3). ¹H NMR (400 MHz, CDCl₃): δ = 8.18 (dd, *J* = 8.8, 2.0 Hz, 1H; Ar-H), 7.68 (dd, *J* = 7.6, 0.8 Hz, 1H; Ar-H), 7.58 (dt, *J* = 8.8, 2.8 Hz, 2H; Ar-H), 7.42-7.34 (m, 2H; Ar-H), 7.29 (d, *J* = 8.4 Hz, 2H; Ar-H), 7.07 (d, *J* = 8.0 Hz, 2H; Ar-H), 6.97 (dt, *J* = 8.8, 2.4 Hz, 2H; Ar-H), 3.89 (s, 3H; OMe), 2.30 (s, 3H; Me) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 161.6 (C), 154.4 (C), 145.7 (C), 142.9 (C), 135.1 (C), 134.1 (C), 132.6 (CH), 129.8 (CH), 127.1 (CH), 125.4 (CH), 122.3 (C), 120.3 (CH), 115.5 (CH), 113.2 (CH), 55.6 (CH₃), 21.8 (CH₃) ppm. IR (KBr): ν = 3007, 2360, 1600, 1491, 1440, 1390, 1249, 1190, 1174, 1074, 1022, 1003, 833 cm⁻¹. MS (EI): *m/z* (%): 378 (20), 223 (100), 180 (9), 133 (17). HRMS: *m/z* [M⁺] calcd for C₂₁H₁₈N₂O₃S: 378.1038. Found: 378.1042.

2-Phenyl-1-tosyl-1*H*-benzimidazole (**16c**)^[15]

148 mg (85%). Colorless needles. m.p. 100-103 °C (from CH₂Cl₂-Hexane), *R_f* = 0.4 (Hexane/EtOAc 7:3). ¹H NMR (400 MHz, CDCl₃): δ = 8.19 (d, *J* = 7.6 Hz, 1H; Ar-H), 7.72 (d, *J* = 7.6 Hz, 1H, Ar-H), 7.61-7.58 (m, 2H; Ar-H), 7.56-7.54 (m, 1H; Ar-H), 7.49-7.36 (m, 4H; Ar-H), 7.31 (d, *J* = 8.4 Hz, 2H; Ar-H), 7.08 (d, *J* = 8.0 Hz, 2H; Ar-H), 2.32 (s, 3H; Me) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 154.2 (C), 145.8 (C), 142.7 (C), 135.1 (C), 134.0 (C), 131.0 (CH), 130.6 (CH), 130.2 (C), 129.8 (CH), 127.8 (CH), 127.1 (CH), 125.6 (CH), 125.4 (CH), 120.5 (CH), 115.3 (CH), 21.7 (CH₃) ppm. IR (KBr): ν = 3055, 2360, 1597, 1448, 1388, 1303, 1192, 1176, 1120, 1084, 1033, 1010, 769 cm⁻¹. MS (EI): *m/z* (%): 348 (40, M⁺), 193 (100), 90 (28). HRMS: *m/z* [M⁺] calcd for C₂₀H₁₆N₂O₂S: 348.0932. Found: 348.0935.

2-[(4-Trifluoromethyl)phenyl]-1-tosyl-1*H*-benzimidazole (16d)

165 mg (79%). Pale yellow needles. m.p. 167-169 °C (from CH₂Cl₂-Hexane), *R*_f = 0.4 (Hexane/EtOAc 8:2). ¹H NMR (400 MHz, CDCl₃): δ = 8.19 (d, *J* = 8.0 Hz, 1H; Ar-H), 7.77-7.71 (m, 5H; Ar-H), 7.46 (td, *J* = 8.0, 7.2, Hz, 1H; Ar-H), 7.41 (t, *J* = 7.2 Hz, 1H; Ar-H), 7.33 (d, *J* = 8.8 Hz, 2H; Ar-H), 7.11 (d, *J* = 8.4 Hz, 2H; Ar-H), 2.33 (s, 3H; Me) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 152.5 (C), 146.2 (C), 142.7 (C), 134.9 (C), 133.9 (C), 133.7 (C), 132.4 (q; ²J_{C,F} = 32.6 Hz, C), 131.4 (CH), 130.0 (CH), 127.0 (CH), 126.1 (CH), 125.7 (CH), 124.7 (q; ³J_{C,F} = 3.4 Hz, CH), 124.1 (q; ¹J_{C,F} = 271 Hz, C), 120.8 (CH), 115.3 (CH), 21.8 (CH₃) ppm; ¹⁹F NMR (376 MHz, CDCl₃): δ = -62.7 (s) ppm. IR (KBr): ν̄ = 3057, 2360, 1448, 1410, 1384, 1325, 1305, 1274, 1188, 1176, 1159, 1109, 1076, 1062, 850 cm⁻¹. MS (EI): *m/z* (%): 461 (47, M⁺), 261 (34), 155 (82), 91 (100). HRMS: *m/z* [M⁺] calcd for C₂₁H₁₅F₃N₂O₂S: 416.0806. Found: 416.0804.

2-*o*-Tolyl-1-tosyl-1*H*-benzimidazole (16e)^[16]

158 mg (87%). Colorless needles. m.p. 153-155 °C (from CH₂Cl₂-Hexane), *R*_f = 0.3 (Hexane/EtOAc 8:2). ¹H NMR (400 MHz, CDCl₃): δ = 8.22 (d, *J* = 8.8 Hz, 1H; Ar-H), 7.75 (d, *J* = 6.8 Hz, 1H; Ar-H), 7.47-7.38 (m, 5H; Ar-H), 7.26-7.21 (m, 2H; Ar-H), 7.16 (t, *J* = 8.4 Hz, 3H; Ar-H), 2.36 (s, 3H; Me), 2.05 (s, 3H; Me) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 152.5 (C), 146.0 (C), 142.4 (C), 139.1 (C), 135.4 (C), 133.3 (C), 130.8 (CH), 130.5 (CH), 130.0 (C), 129.94 (CH), 129.87 (CH), 127.5 (CH), 125.5 (CH), 125.0 (CH), 124.9 (CH), 120.6 (CH), 114.6 (CH), 21.8 (CH₃), 20.0 (CH₃) ppm. IR (KBr): ν̄ = 2920, 2342, 1543, 1450, 1365, 1303, 1269, 1255, 1192, 1174, 1072, 767 cm⁻¹. MS (EI): *m/z* (%): 362 (3, M⁺), 298 (21), 207 (100), 91 (14). HRMS: *m/z* [M⁺] calcd for C₂₁H₁₈N₂O₂S: 362.1089. Found: 362.1092.

2-Mesityl-1-tosyl-1*H*-benzimidazole (16f)^[15]

146 mg (75%). Colorless prisms. m.p. 162-165 °C (from Hexane), *R*_f = 0.5 (Hexane/EtOAc 8:2). ¹H NMR (400 MHz, CDCl₃): δ = 8.26 (d, *J* = 7.2 Hz, 1H; Ar-H), 7.76 (d, *J* = 6.8 Hz, 1H; Ar-H), 7.48-7.38 (m, 4H; Ar-H), 7.17 (d, *J* = 8.4 Hz, 2H; Ar-H), 6.87 (s, 2H; Ar-H), 6.87 (s, 2H; Ar-H), 2.38 (s, 3H; Me), 2.36 (s, 3H; Me), 1.75 (s, 6H; Me) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 151.9 (C), 146.0 (C), 142.4 (C), 140.0 (C), 138.8 (C), 135.3 (C), 133.2 (C), 129.8 (CH), 128.0 (CH), 127.8 (CH), 126.9 (C), 125.3 (CH), 124.7 (CH), 120.6 (CH), 114.3 (CH), 21.9 (CH₃), 21.6 (CH₃), 20.0 (CH₃) ppm. IR (KBr): ν̄ = 2920, 2359, 1610, 1545, 1448, 1383, 1251, 1230, 1190, 1180, 1165, 1124, 1091, 1060, 1014, 812 cm⁻¹. MS (EI): *m/z* (%): 390 (4, M⁺), 326 (22), 235 (100), 91 (11). HRMS: *m/z* [M⁺] calcd for C₂₃H₂₂N₂O₂S: 390.1402. Found: 390.1405.

2-(Thiophen-2-yl)-1-tosyl-1*H*-benzimidazole (16g)

124 mg (70%). Colorless oil. $R_f = 0.4$ (Hexane/EtOAc 8:2). ^1H NMR (400 MHz, CDCl_3): $\delta = 8.20$ (d, $J = 8.0$ Hz, 1H; Ar-H), 7.80 (d, $J = 3.2$ Hz, 1H; Ar-H), 7.70 (dd, $J = 5.6, 2.0$ Hz, 1H; Ar-H), 7.53 (d, $J = 4.8$ Hz, 1H; Ar-H), 7.43-7.34 (m, 4H; Ar-H), 7.18 (dd, $J = 3.6, 1.2$ Hz, 1H; Ar-H), 7.08 (d, $J = 8.4$ Hz, 2H; Ar-H), 2.31 (s, 3H; Me) ppm; ^{13}C NMR (100 MHz, CDCl_3): $\delta = 147.9$ (C), 145.9 (C), 142.6 (C), 134.8 (C), 134.3 (C), 133.4 (CH), 130.2 (C), 130.0 (CH), 129.9 (CH), 127.6 (CH), 127.0 (CH), 125.7 (CH), 125.6 (CH), 120.4 (CH), 115.5 (CH), 21.8 (CH_3) ppm. IR (neat): $\nu \sim = 3074, 2357, 1556, 1487, 1448, 1417, 1387, 1298, 1273, 1255, 1232, 1215, 1151, 1120, 1089, 1062, 1041 \text{ cm}^{-1}$. MS (EI): m/z (%): 354 (25, M^+), 199 (100), 172 (16), 90 (27). HRMS: m/z [M $^+$] calcd for $\text{C}_{18}\text{H}_{14}\text{N}_2\text{O}_2\text{S}_2$: 354.0497. Found: 354.0495.

2-Cyclohexyl-1-tosyl-1*H*-benzimidazole (16h)^[15]

127 mg (72%). Colorless prisms. m.p. 125-128 °C (from Hexane), $R_f = 0.5$ (Hexane/EtOAc 8:2). ^1H NMR (400 MHz, CDCl_3): $\delta = 8.05\text{-}8.03$ (m, 1H; Ar-H), 7.74 (d, $J = 8.0$ Hz, 2H; Ar-H), 7.67-7.65 (m, 1H; Ar-H), 7.34-7.30 (m, 2H; Ar-H), 7.26 (d, $J = 8.4$ Hz, 2H; Ar-H), 3.51-3.45 (m, 1H; Cy), 2.38 (s, 3H; Me), 1.93-1.83 (m, 4H; Cy), 1.77-1.62 (m, 3H; Cy), 1.46-1.30 (m, 3H; Cy) ppm; ^{13}C NMR (100 MHz, CDCl_3): $\delta = 159.8$ (C), 145.9 (C), 142.2 (C), 136.0 (C), 133.0 (C), 130.3 (CH), 126.7 (CH), 124.8 (CH), 124.7 (CH), 119.9 (C), 114.1 (C), 38.3 (CH), 32.7 (CH_2), 26.5 (CH_2), 25.9 (CH_2), 21.8 (CH_3) ppm. IR (KBr): $\nu \sim = 2929, 2848, 2359, 1597, 1452, 1369, 1246, 1228, 1193, 1165, 1120, 1045, 744 \text{ cm}^{-1}$. MS (EI): m/z (%): 354 (4, M^+), 286 (13), 199 (100), 145 (20). HRMS: m/z [M $^+$] calcd for $\text{C}_{20}\text{H}_{22}\text{N}_2\text{O}_2\text{S}$: 354.1402. Found: 354.1439.

2-Methyl-1-tosyl-1*H*-benzimidazole (16i)^[17]


105 mg (73%). Colorless prisms. m.p. 122-124 °C (from Acetone-Hexane), $R_f = 0.4$ (Hexane/EtOAc 7:3). ^1H NMR (400 MHz, CDCl_3): $\delta = 8.02\text{-}8.00$ (m, 1H; Ar-H), 7.80 (d, $J = 8.8$ Hz, 2H; Ar-H), 7.62-7.60 (m, 1H; Ar-H), 7.36-7.27 (m, 4H; Ar-H), 2.80 (s, 3H; Me), 2.38 (s, 3H; Me) ppm; ^{13}C NMR (100 MHz, CDCl_3): $\delta = 151.5$ (C), 146.1 (C), 142.0 (C), 135.5 (C), 133.3 (C), 130.4 (CH), 126.9 (CH), 124.9 (CH), 124.7 (CH), 119.8 (CH), 113.6 (CH), 21.8 (CH_3), 17.1 (CH_3) ppm. IR (KBr): $\nu \sim = 2924, 2360, 1545, 1454, 1384, 1371, 1247, 1172, 1149, 1087, 999 \text{ cm}^{-1}$. MS (EI): m/z (%): 286 (63), 155 (57), 131 (17), 91 (100). HRMS: m/z [M $^+$] calcd for $\text{C}_{15}\text{H}_{14}\text{N}_2\text{O}_2\text{S}$: 286.0776. Found: 286.0780.

5. References


1. Xu, Z-M.; Li, H-X.; Young, D. J.; Zhu D-L.; Li, H-Y.; Lang, J-P. *Org. Lett.* **2019**, *21*, 237–241.
2. Saha, S.; Moorthy, J. N. *Tetrahedron Lett.* **2010**, *51*, 912–916.
3. Bresien, J.; Hering-Junghans, C.; Schulz, A.; Thomas, M.; Villinger, A. *Organometallics* **2018**, *37*, 2571–2580.
4. Moiseev, M. D.; Malysheva, Y. B.; Shavyrin, A. S.; Kurskii, Y. A.; Gushchin, A. V. *J. Organomet. Chem.*, **2005**, *690*, 3652–3663.
5. Ueda, S.; Nagasawa, H. *Angew. Chem. Int. Ed.* **2008**, *47*, 6411–6413.
6. Shi, W-M.; Li, X-H.; Liang, C.; Mo, D-L. *Adv. Synth. Catal.* **2017**, *359*, 4129–4135.
7. Layek, S.; Agrahari, B.; Kumar, A.; Dege, N.; Pathak, D. D. *Inorg. Chim. Acta* **2020**, *500*, 119222.
8. Liu, N.; Wang, Z-X. *J. Org. Chem.* **2011**, *76*, 10031–10038.
9. Zhou, Q.; Liu, S.; Ma, M.; Cui, H-Z.; Hong, X.; Huang, S.; Zhang, J-F.; Hou, X-F. *Synthesis* **2018**, *50*, 1315–1322.
10. Kantam, M. L.; Venkanna, G. T.; Kumar, K. B. S.; Balasubrahmanyam, V.; Bhargava, S. *Synlett* **2009**, *11*, 1753–1756.
11. Li, K-L.; Du, Z-B.; Guo, C-C.; Chen, Q-Y. *J. Org. Chem.* **2009**, *74*, 3286–3292.
12. Shi, Y.; Zhou, Q.; Du, F.; Fu, Y.; Du, Y.; Fang, T.; Chen, G. *Tetrahedron Lett.* **2019**, *60*, 151082.
13. Boissarie, P. J.; Hamilton, Z. E.; Lang, S.; Murphy, J. A.; Suckling, C. J. *Org. Lett.* **2011**, *13*, 6256–6259.
14. Kumar, D.; Pilania, M.; Arun, V.; Poonya, S. *Org. Biomol. Chem.* **2014**, *12*, 6340–6344.
15. Hu, Z.; Zhao, T.; Wang, M.; Wu, J.; Yu, W.; Chang, J. *J. Org. Chem.* **2017**, *82*, 3152–3158.
16. Xu, L.; Wang, L.; Feng, Y.; Li, Y.; Yang, L.; Cui, X. *Org. Lett.* **2017**, *19*, 4343–4346.
17. Kljajic, M.; Puschnig, J. G.; Weber, H.; Breinbauer, R. *Org. Lett.* **2017**, *19*, 126–129.

6. Copies of ^1H , ^{13}C and ^{19}F NMR spectra


^1H NMR of **8a**




^{13}C NMR of **8a**




¹H NMR of **8b**




¹³C NMR of **8b**




¹H NMR of **8c**




¹³C NMR of **8c**




¹H NMR of **8d**




¹³C NMR of **8d**




¹H NMR of **8e**




¹³C NMR of **8e**




¹H NMR of **8f**




¹³C NMR of **8f**




¹⁹F NMR of **8f**




¹H NMR of **8g**




¹³C NMR of **8g**




¹H NMR of **8h**




¹³C NMR of **8h**




¹H NMR of **8i**




¹³C NMR of **8i**




¹H NMR of **8j**




¹³C NMR of **8j**




¹H NMR of **8k**




¹³C NMR of **8k**




¹H NMR of **8l**




¹³C NMR of **8l**




¹H NMR of **8m**




¹³C NMR of **8m**




¹H NMR of **8n**




¹³C NMR of **8n**




¹H NMR of **8o**




¹³C NMR of **8o**




¹H NMR of **8p**




¹³C NMR of **8p**




¹H NMR of **8q**





¹³C NMR of **8q**




¹⁹F NMR of **8q**




¹H NMR of **8r**




¹H NMR of **8s**




¹³C NMR of **8s**




¹H NMR of **8t**




¹³C NMR of **8t**




¹H NMR of **8u**




¹³C NMR of **8u**




¹H NMR of **8v**




¹³C NMR of **8v**




¹H NMR of **8w**




¹³C NMR of **8w**




¹H NMR of **9**




¹³C NMR of **9**




¹H NMR of **12**




¹³C NMR of **12**




¹H NMR of **13** (Tafamidis)




¹³C NMR of **13** (Tafamidis)




¹H NMR of **16b**




¹³C NMR of **16b**




¹H NMR of **16c**




¹³C NMR of **16c**




¹H NMR of **16d**




¹³C NMR of **16d**




¹⁹F NMR of **16d**




¹H NMR of **16e**




¹³C NMR of **16e**




¹H NMR of **16f**




¹³C NMR of **16f**




¹H NMR of **16g**




¹³C NMR of **16g**




¹H NMR of **16h**




¹³C NMR of **16h**



¹H NMR of **16i**



¹³C NMR of **16i**



7. NMR Experiments

Given in Figure S1 are results of NMR experiments for reaction mixture (6 h) showing the in situ generation of **17**.




Figure S1. Detected reaction intermediate by ^1H NMR in CDCl_3 (aromatic region).